Name: Medical Developments International (MVP) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

MVP

Pharmaceuticals, Biotechnology & Life Sciences

Medical Developments International

Short interest: 0.00%; 0.00 pp 30d; as of 8 Oct 2026
Reported shorts: 152
Shares on issue: 112.658M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Medical Developments International

Medical Developments International (MVP) is a pharmaceutical company focused on developing and distributing innovative medical devices. They operate in the acute pain and respiratory illness treatment sectors, aiming to improve patient care globally. MDI partners with organizations like CSIRO to drive industry-leading product development.

Company profile →

Medical Developments International (ASX:MVP) has 0.00% of its shares on issue reported as short positions as of 8 Oct 2026, or about 152 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 3.86% in September 2021. MVP is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads MVP today

Zanger BreakoutWatchScore 25rank 964 of 1942
CAN SLIMWatchScore 25rank 442 of 1541
Minervini Trend TemplateNot a candidate
Crowded-Short BreakoutNot a candidate
Quality compoundersWatchScore 23rank 651 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

MVP fundamentals

In the year to 30 Jun 2026, Medical Developments International (ASX:MVP) recorded revenue of A$42.6M and net profit after tax of A$626.0K. A year earlier it recorded revenue of A$39.1M and net profit after tax of A$94.0K. Year-on-year growth: revenue +9.0% (FY), EPS +488.9% (FY). Net margin 1.5% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →